117 related articles for article (PubMed ID: 7574268)
1. [Parkinson disease and the neuronal dopamine uptake complex].
Costentin J
Ann Pharm Fr; 1995; 53(4):145-54. PubMed ID: 7574268
[TBL] [Abstract][Full Text] [Related]
2. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
3. [Mechanisms and treatments of Parkinson disease].
Pollak P
Rev Prat; 1997 May; 47(10):1068-76. PubMed ID: 9208669
[TBL] [Abstract][Full Text] [Related]
4. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
5. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease.
Murrell W; Wetzig A; Donnellan M; Féron F; Burne T; Meedeniya A; Kesby J; Bianco J; Perry C; Silburn P; Mackay-Sim A
Stem Cells; 2008 Aug; 26(8):2183-92. PubMed ID: 18535154
[TBL] [Abstract][Full Text] [Related]
6. Oxidation of dopamine to aminochrome as a mechanism for neurodegeneration of dopaminergic systems in Parkinson's disease. Possible neuroprotective role of DT-diaphorase.
Graumann R; Paris I; Martinez-Alvarado P; Rumanque P; Perez-Pastene C; Cardenas SP; Marin P; Diaz-Grez F; Caviedes R; Caviedes P; Segura-Aguilar J
Pol J Pharmacol; 2002; 54(6):573-9. PubMed ID: 12866711
[TBL] [Abstract][Full Text] [Related]
7. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
St-Hilaire M; Landry E; Lévesque D; Rouillard C
Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
[TBL] [Abstract][Full Text] [Related]
8. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
9. The role of striatal metabotropic glutamate receptors in degeneration of dopamine neurons: review article.
Gołembiowska K; Konieczny J; Ossowska K; Wolfarth S
Amino Acids; 2002; 23(1-3):199-205. PubMed ID: 12373538
[TBL] [Abstract][Full Text] [Related]
10. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease.
Uhl GR
Ann Neurol; 1998 May; 43(5):555-60. PubMed ID: 9585349
[No Abstract] [Full Text] [Related]
11. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
Liu B; Dluzen DE
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
[TBL] [Abstract][Full Text] [Related]
12. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
[TBL] [Abstract][Full Text] [Related]
13. Striatal dopaminergic neurons are lost with Parkinson's disease progression.
Porritt MJ; Kingsbury AE; Hughes AJ; Howells DW
Mov Disord; 2006 Dec; 21(12):2208-11. PubMed ID: 17029264
[TBL] [Abstract][Full Text] [Related]
14. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
[TBL] [Abstract][Full Text] [Related]
16. Neural degeneration and the transport of neurotransmitters.
Edwards RH
Ann Neurol; 1993 Nov; 34(5):638-45. PubMed ID: 7902065
[TBL] [Abstract][Full Text] [Related]
17. Methylphenylpyridium ion (MPP+) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon.
Sawada H; Shimohama S; Tamura Y; Kawamura T; Akaike A; Kimura J
J Neurosci Res; 1996 Jan; 43(1):55-62. PubMed ID: 8838574
[TBL] [Abstract][Full Text] [Related]
18. [Dopamine dysregulation syndrome in Parkinson's disease].
Borg M; Bayreuther C
Rev Neurol (Paris); 2008 Apr; 164(4):310-21. PubMed ID: 18439923
[TBL] [Abstract][Full Text] [Related]
19. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
Calabresi P; Mercuri NB; Sancesario G; Bernardi G
Brain; 1993 Apr; 116 ( Pt 2)():433-52. PubMed ID: 8096420
[TBL] [Abstract][Full Text] [Related]
20. Neuronal transplantation and neurotrophic factors in the treatment of Parkinson's disease--update February 1995.
Kupsch A; Oertel WH; Earl CD; Sautter J
J Neural Transm Suppl; 1995; 46():193-207. PubMed ID: 8821056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
